Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicloralurea SCHEMBL134347 | 0.85 | HPGD (0.45) | HPGDLMNACYP2C19 | |
| Dicloralurea SCHEMBL2674558 | 0.78 | HPGD (0.41) | HPGDLMNA | |
| Dicloralurea SCHEMBL6534881 | 0.76 | HPGD (0.41) | HPGDCYP2C19 | |
| Dicloralurea SCHEMBL17968228 | 0.76 | HPGD (0.41) | HPGD | |
| SCHEMBL25292405 | 0.75 | HPGD (0.47) | HPGDLMNACYP2C19 | |
| Dicloralurea SCHEMBL3965395 | 0.74 | HPGD (0.40) | HPGDLMNACYP2C19 | |
| Dicloralurea SCHEMBL4075855 | 0.74 | HPGD (0.40) | HPGD | |
| Dicloralurea SCHEMBL5418303 | 0.73 | HPGD (0.39) | HPGDCYP2C19 | |
| Dicloralurea SCHEMBL4966646 | 0.73 | HPGD (0.39) | HPGD | |
| Dicloralurea SCHEMBL5099542 | 0.70 | EPHX1 (0.40) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | claimed |
| EP-2007741-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | Xytis Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | claimed |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | OXFORD FINANCE CORPORATION | 2008-02-14 | — | — | US | claimed |
| WO-2007109288-A2 | ENANTIOMERICALLY PURE R-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007109289-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12433896-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | GABA THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230263805-A1 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | GABA THERAPEUTICS INC (US) | 2023-08-24 | — | — | US | disclosed |
| US-11672805-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | GABA THERAPEUTICS INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-10925879-B2 | Methods of treating developmental disorders and/or seizure disorders with etifoxine | OVID THERAPEUTICS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200405726-A1 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | GABA THERAPEUTICS INC. | 2020-12-31 | — | — | US | disclosed |
| CN-1143318-A | Transdermal device containing polyvinylpyrrolidone as dissolution enhancer | NOVEN PHARMA (US) | 1997-02-19 | — | — | CN | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433896-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | CYP2F1, CYP3A5, CYP4F3 | HPGD 121/4885LMNA 4609/4885CYP2C19 16/4885 |
| US-20200405726-A1 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | CYP2F1, CYP3A5, CYP4F3 | HPGD 121/4885LMNA 4609/4885CYP2C19 16/4885 |
| US-11672805-B2 | Deuterated analogs of etifoxine, their derivatives and uses thereof | CYP2F1, CYP3A5, CYP4F3 | HPGD 121/4885LMNA 4609/4885CYP2C19 16/4885 |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, CYP2C9, CYP3A5 | HPGD 275/4885LMNA 3721/4885CYP2C19 5/4885 |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, GRIK5, CYP3A5 | HPGD 341/4885LMNA 3863/4885CYP2C19 7/4885 |
| US-20230263805-A1 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | CYP2F1, CYP3A5, CYP4F3 | HPGD 121/4885LMNA 4609/4885CYP2C19 16/4885 |
| US-10925879-B2 | Methods of treating developmental disorders and/or seizure disorders with etifoxine | GRIK5, SLC1A2, GRIN2D | HPGD 711/4885LMNA 4618/4885CYP2C19 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.